Quarterly Activities/Appendix 4C Cash Flow Report
Released
Released
Announcement PDF
Company Announcement
IMAGION BIOSYSTEMS LIMITED
ASX: IBX
30 April 2024
Quarterly Activity Report – quarter ending 31 March 2024
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through
the early detec on of cancer, provides this business update for shareholders and the markets.
On 29 February 2024, the company lodged unaudited year end financials but did not lodge the audited
financial report as required which resulted in a suspension of trading by the ASX on 31 March 2024. As
previously communicated, in the face of challenging market and financial condi ons the Company has
been pursuing a wide range of strategic financial and restructuring op ons while undertaking
significant cost reduc on measures since last October.
The cost reduc on measures include a significantly reduced workforce, no director fees and cessa on
of nanopar cle manufacturing whilst the Company seeks a pathway to capitaliza on. At this me, the
expressions of interest ranging from refinancing, partnering or acquisi on have yet to materialize to
change the Company’s financial posi on.
“We understand the impact the extended suspension of trading of our Company’s shares may have for
our shareholders”, said Bob Proulx, Execu ve Chairman, “and we thank our shareholders for their
pa ence as we con nue to work through our current financial situa on.”
If no partnering or acquisi on offers are resolved, the Company will need to cease opera on.
Summary of cash flows
Imagion’s cash balance as at 31 December 2023 was AU$94k, a decrease of AU$133k from the prior
quarter. The Company reported an opera ng cash ou low of AU$142k in the quarter. These cash flows
were funded by $694k receipts from customers (nanopar cle sales).
Payroll costs were significantly reduced with the business maintaining a small level of staffing during
Q1 2024 to oversee remaining nanopar cle manufacturing contracts.
Whilst receipts from customers remained strong all nanopar cle orders have now been filled and our
manufacturing capabili es are now on hold as of the date of this report.
The Company also paid $27k to related par es and their associates during the quarter for execu ve
director salaries (being Dr Isaac Bright’s final payment). However, it should be noted that all directors
suspended their fees effec ve 1st December 2023, and that Mr. Proulx is receiving no compensa on at
this me as a director or for his execu ve role.
ENDS
About Imagion Biosystems
Established in 2017 and headquartered in the San Diego, California, US, Imagion Biosystems is an ASXlisted company dedicated to developing innova ve medical imaging technologies for various cancer
types. Imagion Biosystems is advancing clinical development of its MagSense® pla orm technology to
revolu onize cancer diagnosis, introducing molecular imaging to MRI. The Company’s lead program
has demonstrated its innova ve technology embodied in MagSense® HER2 Imaging Agent (MSH2IA)
is safe and well-tolerated in pa ents diagnosed with HER2+ breast cancer. Imagion Biosystems’
MagSense® pipeline includes prostate cancer, ovarian cancer, pancrea c cancer, and brain cancer
programs.
For more informa on, visit h ps://imagionbiosystems.com/investor-hub/
AuthorisaƟon & AddiƟonal informaƟon
This announcement was authorised by the Disclosure Commi ee of Imagion Biosystems Limited.
Media & Investor RelaƟons:
Geoff Hollis, CFO and Company Secretary
geoff.hollis@imagionbio.com
Rule 4.7B
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
Imagion Biosystems Limited
ABN
Quarter ended (“current quarter”)
42 616 305 027
31 March 2024
Consolidated statement of cash flows
Current quarter
$A’000
Year to date
(3 months)
$A’000
694
694
(41)
(41)
(b) product manufacturing and operating
costs
-
-
(c) advertising and marketing
-
-
(d) leased assets
-
-
(e) staff costs
(695)
(695)
(f)
(158)
(158)
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
(a) research and development
administration and corporate costs
1.3
Dividends received (see note 3)
-
-
1.4
Interest received
-
-
1.5
Interest and other costs of finance paid
(1)
(1)
1.6
Income taxes paid
-
-
1.7
Government grants and tax incentives
28
28
1.8
Other (provide details if material)
32
32
1.9
Net cash from / (used in) operating
activities
(142)
(142)
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
other non-current assets
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 1
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
2.2
Current quarter
$A’000
Year to date
(3 months)
$A’000
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
Proceeds from disposal of:
other non-current assets
2.3
Cash flows from loans to other entities
-
-
2.4
Dividends received (see note 3)
-
-
2.5
Other (provide details if material)
-
-
2.6
Net cash from / (used in) investing
activities
-
-
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
-
-
3.2
Proceeds from issue of convertible debt
securities
-
-
3.3
Proceeds from exercise of options
-
-
3.4
Transaction costs related to issues of
equity securities or convertible debt
securities
-
-
3.5
Proceeds from borrowings
-
-
3.6
Repayment of borrowings
-
-
3.7
Transaction costs related to loans and
borrowings
-
-
3.8
Dividends paid
-
-
3.9
Other (provide details if material)
-
-
3.10
Net cash from / (used in) financing
activities
-
-
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
227
227
(142)
(142)
-
-
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
4.3
Net cash from / (used in) investing activities
(item 2.6 above)
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 2
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
Current quarter
$A’000
Year to date
(3 months)
$A’000
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
-
-
4.5
Effect of movement in exchange rates on
cash held
9
9
4.6
Cash and cash equivalents at end of
period
94
94
5.
Reconciliation of cash and cash
equivalents
Current quarter
$A’000
Previous quarter
$A’000
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
5.1
Bank balances
94
227
5.2
Call deposits
-
-
5.3
Bank overdrafts
-
-
5.4
Other (provide details)
-
-
5.5
Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
94
227
6.
Payments to related parties of the entity and their
associates
Current quarter
$A'000
6.1
Aggregate amount of payments to related parties and their
associates included in item 1
27
6.2
Aggregate amount of payments to related parties and their
associates included in item 2
-
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an
explanation for, such payments.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 3
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
7.
Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
$A’000
Amount drawn at
quarter end
$A’000
7.1
Loan facilities
-
-
7.2
Credit standby arrangements
-
-
7.3
Other (please specify)
15,000
3,500
7.4
Total financing facilities
15,000
3,500
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
N/A
The Company has a $15 million convertible note facility with $11.5 million undrawn at
quarter end. The remaining $11.5 million is subject to use of the Company’s 15%
placement capacity as well as mutual consent with the lender and the Company prior to
drawdown. Given the lender’s floor price is now above the Company’s share price there is
minimal likelihood of being able to draw further on this facility in the short-term. The facility
is secured over the Company’s assets and has no coupon payable.
8.
Estimated cash available for future operating activities
$A’000
8.1
Net cash from / (used in) operating activities (item 1.9)
(142)
8.2
Cash and cash equivalents at quarter end (item 4.6)
94
8.3
Unused finance facilities available at quarter end (item 7.5)
-
8.4
Total available funding (item 8.2 + item 8.3)
94
8.5
Estimated quarters of funding available (item 8.4 divided by
item 8.1)
0.7
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer: The Company has been reducing its work force since October 2023 and continues
to reduce its cost base. Recent nanoparticle manufacturing orders have been filled
and these activities have now ceased. As of end April 2024 the Company will be
vacating its premises. The main focus in the short-term is to continue to find a
pathway to recapitalisation and reduce amounts owing to creditors.
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer: The Company is anticipating receipts from nanoparticles sales (already shipped),
equipment sales and its R&D tax incentive in Q2 2024 totalling ~$0.7 million. This
will not clear current creditor balances and the Company has therefore been in
discussions with several parties looking to restructure the Company. To date these
haven’t resulted in a successful outcome and further updates will be provided
should any of these discussions result in an outcome that can provide a pathway
forward for the Company.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 4
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
8.6.3
Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer: The continuation of the Company’s operations and our ability to meet our
objectives will be dependent on successful execution of the initiatives outlined in the
answer to 8.6.2. Refer to the accompanying announcement for further details.
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
30 April 2024
Date:
...................................................................................
By the Board of Imagion Biosystems Limited
Authorised by: ...................................................................................
(Name of body or officer authorising release – see note 4)
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4.
If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5.
If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 5
Share your feedback
Discover